US/UK/Canada

Share

Contacts

  • Rikard Akhtarzand

    CEO


    Grev Turegatan 3, floor 4, SE 114 46 Stockholm, Sweden
    08 128 766 00
    http://www.addvisegroup.com

    • Quotes

    Strengthening ADDvise with Fredrik Mella enables us to continue to accelerate our growth rate. He will complement our management team with his international experience from the Medtech industry, and I believe Fredrik will be a good leader and coach for our subsidiaries' CEOs.
    Rikard Akhtarzand, CEO
    ADDvise is a successful company in the middle of an exciting growth journey. I look forward to make a difference and contribute with my experiences
    Fredrik Mella
    Pick a time period -
    Tags ( Active)

    ADDvise publishes prospectus and applies for admission to trading of bonds on Nasdaq Stockholm

    On 4 April 2024, ADDvise Group AB (publ) (“ADDvise”) issued senior secured bonds in an amount of USD 60 million, under a total framework of USD 200 million (the “Bonds”). Pursuant to the terms and conditions for the Bonds, ADDvise has undertaken to apply for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm. For this purpose, the company has prepared a listing prospectus, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available at the company’s website www.addvisegroup.com and at the

    Interim report 2024, January 1 – March 31

    The first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved.January – March 2024 Net revenue for the period was SEK 413.4 million (310.5), an increase of 33.1% On an organic basis, net revenue declined by 9.5%. Excluding pharmaceuticals, organic growth was 3.6%. EBITDA for the period was SEK 99.1 million (84.2) Profit/loss

    ADDvise receives allocation decision worth EUR 1.25 million

    ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from the Kanta-Häme region worth EUR 1.25 million. The allocation decision pertains to the delivery of x-ray equipment to three hospitals in the region during 2024 and early 2025.   The allocation decision is subject to a customary appeals period.   For further information, please contact: Rikard Akhtarzand, CEO +46 (0) 76-525 90 71 rikard.akhtarzand@addvisegroup.se   Important information This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the

    Invitation to presentation of interim report January 1 – March 31, 2024

    ADDvise Group’s interim report for the period January 1 – March 31, 2024 will be published on April 18, 2024 at 07:45 (CEST).   Investors, analysts, and other stakeholders are invited to a webcast and conference call at 14:00 (CEST) / 08:00 AM (EST) the same day where CEO Rikard Akhtarzand and CFO Oliver Humlen will present the report.   Webcast If you wish to participate via webcast, please use the link below.   https://ir.financialhearings.com/addvise-group-q1-2024/register   Conference call If you wish to participate via conference call, please register via

    ADDvise Group publishes annual report and sustainability report for 2023

    Today, ADDvise Group AB (publ) is publishing the annual report and the sustainability report for 2023. Both reports are available on ADDvise’s website: www.addvisegroup.com.   The annual report and the sustainability report are published in Swedish and English. The Swedish versions represent the originals.   For further information, please contact:   Rikard Akhtarzand, CEO +46 (0)76-525 90 71 rikard.akhtarzand@addvisegroup.se   Oliver Humlen, CFO +46 (0)70-916 26 97 oliver.humlen@addvisegroup.se   About ADDvise ADDvise is an international life

    Notice to the annual general meeting of ADDvise Group AB (publ)

    ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 3 May 2024 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATIONShareholders wishing to attend the annual general meeting must: i)          be registered in the share register kept by Euroclear Sweden AB on the record date 24 April 2024, or, if the shareholder has had his/her shares registered in the name of a nominee, request that the nominee registers the shares for voting purposes in such time that the registration is completed no

    ADDvise issues new USD senior secured bonds and partially repurchases outstanding SEK senior secured bonds

    ADDvise Group AB (publ) (the “Company”) announces today that it has successfully placed senior secured bonds in an amount of USD 60 million under a framework of USD 200 million with a tenor of 3 years (the “New Bonds” or the “Bond Issue”). The New Bonds will carry floating rate interest of SOFR plus 4.25 per cent per annum and were issued at par. The Bond Issue saw strong demand from a broad base of Nordic and international institutional investors and was significantly oversubscribed. As announced on 18 March 2024, the Company offered a partial buy-back to the holders of the Company’s

    ADDvise considers issuance of new USD senior secured bonds and partial buy-back offer in outstanding SEK senior secured bonds

    ADDvise Group AB (publ) (“ADDvise” or the “Company”) has mandated Pareto Securities AB and Skandinaviska Enskilda Banken AB (publ) to arrange a series of credit investor meetings commencing on 18 March 2024. To better align the Company’s long-term funding with its operational currency exposure, the Company considers, subject to inter alia market conditions, the issuance of a new 3-year senior secured bond in an amount of approximately USD 60 million (“New Bonds”) coupled with a partial buy-back offer in its outstanding bond (ISIN: SE0020180271) (“SEK Bonds”) of up to SEK 450 million (the “

    ADDvise Group completes a directed new share issue of B shares of approximately SEK 100 million

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.ADDvise Group AB (publ) (“ADDvise” or the “Company”) has, in accordance with the intention announced in the Company’s press release earlier today, carried out

    ADDvise Group explores the conditions for carrying out a directed new share issue of B shares of approximately SEK 100 million

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.ADDvise Group AB (publ) (“ADDvise” or the “Company”) has appointed ABG Sundal Collier AB ("ABG Sundal Collier") and Pareto Securities AB (“Pareto Securities”)

    The nomination committee’s proposal for board of directors of ADDvise Group AB (publ)

    To the annual general meeting (AGM) of ADDvise Group AB (publ) on 3 May 2024, the nomination committee has decided to propose re-election of Fredrik Celsing, Staffan Torstensson, Johanne Brændgaard and Anna Ljung as members of the board of directors. In addition, the nomination committee proposes election of Thomas Eklund. Erland Pontusson has declined re-election.   It is proposed that Staffan Torstensson is re-elected chairman of the board of directors.   Thomas Eklund has a master’s degree in Economic and Business Administration from Stockholm School of Economics. Thomas Eklund

    Year-end report 2023, January 1-December 31

    ADDvise delivers its strongest quarter to date and surpasses financial targets for 2023. Net sales increased by 24% and EBITDA amounted to a record SEK 126 million, corresponding to an EBITDA margin of 32%.October-December 2023 Net revenue for the period was SEK 397.0 million (320.3), an increase of 24.0%. On an organic basis, net revenue declined by 15.8%. EBITDA for the period was SEK 126.1 million (90.4). Profit/loss for the period was SEK 29.9 million (28.1). Earnings per share for the period amounted to SEK 0.16 (0.16). Cash flow from Operations for the period was SEK 77.

    Invitation to presentation of year-end report January 1 – December 31, 2023

    ADDvise Group’s year-end report for the period January 1 – December 31, 2023 will be published on February 22, 2024 at 07:45 (CET). Investors, analysts and other stakeholders are invited to a webcast and conference call at 14:00 (CET) / 08:00 AM (ET) the same day where CEO Rikard Akhtarzand and CFO Oliver Humlen will present the report.   Webcast If you wish to participate via webcast, please use the link below.   https://ir.financialhearings.com/addvise-group-q4-2023/register   Conference call If you wish to participate via conference call, please register via

    ADDvise receives order worth EUR 2.1 million

    ADDvise Group’s subsidiary Labplan has received an order from the pharmaceutical company Eli Lilly. The order is worth approximately EUR 2.1 million and involves advanced laboratory instruments for quality control purposes. The instruments will be used in a new manufacturing facility for biologic pharmaceuticals in Limerick, Ireland. Delivery of the order is scheduled to the fourth quarter 2024.  For further information, please contact: Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information This information is information that

    ADDvise publishes prospectus and applies for admission to trading of bonds on Nasdaq Stockholm

    On 20 November 2023, ADDvise Group successfully issued senior secured bonds in an amount of SEK 450 million, under a total framework of SEK 2,000 million. Following the bond issue, in total SEK 1,450 million is outstanding under the framework. Pursuant to the terms and conditions for the bonds, ADDvise has undertaken to apply for admission to trading of the bonds on the corporate bond list of Nasdaq Stockholm. For this purpose, the company has prepared a listing prospectus, which today has been approved by the Swedish Financial Supervisory Authority. The prospectus is available at the

    ADDvise receives order worth USD 2.5 million

    ADDvise Group’s subsidiary MRC Systems has received an order from SaudiVax. The company is a biotechnology company specialized in the development and production of vaccines and biopharmaceuticals. The order is worth approximately USD 2.5 million and involves design, installation, and commissioning of a cleanroom and associated accessories. The facility is located in the Kingdom of Saudi Arabia and will be used for pharmaceutical manufacturing. Delivery of the order is scheduled during 2024.  For further information, please contact: Rikard Akhtarzand, CEO+46 765-25 90 71rikard.

    ADDvise receives order worth USD 3 million

    ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Leader Life Sciences, part of Dubai-based Leader Healthcare Group. Leader Life Sciences is a specialist company aiming to introduce ground-breaking scientific technologies and solutions in the fields of biomedical sciences, biotechnology, drug discovery, environmental sciences, and precision medicine. The order is worth approximately USD 3 million and involves the design, supply, installation, and commissioning of a cleanroom and associated accessories for a new biotechnology research facility based in Abu Dhabi.

    ADDvise acquires Labplan Ltd.

    ADDvise Group has entered into a share purchase agreement with the owners of Labplan Ltd. (“Labplan”) regarding the acquisition of all shares of Labplan. Closing takes place today. Labplan, based in Kildare, Ireland, is a distributor of specialized advanced instruments, consumables and service to the life science and biopharmaceutical industry. The company serves large multi-national pharma companies as well as government-backed research institutions in Ireland and Northern Ireland. Labplan’s revenue for the last twelve months per October 31, 2023, amounted to EUR 16.9 million, with

    ADDvise decides not to complete the acquisition of Innovative Endoscopy Components, LLC.

    Innovative Endoscopy Components, LLC. which ADDvise signed a letter of intent to acquire on June 15, 2023, has during the subsequent due diligence not performed in line with initial expectations as regards profitability. ADDvise and the sellers have therefore agreed to terminate discussions. For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Hanna Myhrman, General Counsel+46 709 82 92 23hanna.myhrman@addvisegroup.se Important information This information is by ADDvise Group AB required to disclose under the

    ADDvise acquires Axelerist, Inc.

    ADDvise Group has entered into a share purchase agreement with the owner of Axelerist, Inc. (“Axelerist”) regarding the acquisition of all shares of Axelerist. Closing of the acquisition takes place today. Axelerist, based in Yorktown Heights, New York, is a leading provider of tailored rental and purchase solutions of MedTech- and laboratory equipment for clinical studies. Customers consist of contract research organisations (CRO) and biotech- and pharmaceutical companies. Axelerist’s revenue for the last twelve months per October 31, 2023, amounted to USD 8.7 million, with an EBITDA

    ADDvise Group successfully issues subsequent senior secured bonds of SEK 450 million

    ADDvise Group AB (publ) has successfully issued subsequent senior secured bonds of SEK 450 million under its existing bond loan with ISIN SE0020180271. Following the bond issue, in total SEK 1,450 million will be outstanding under the framework. The subsequent bonds was priced at 101.75% of par and carry a floating interest rate of STIBOR 3m plus 5.50 per cent per annum. The settlement date for the bond issue is expected to be 20 November 2023. The bond issue was met with strong demand from Nordic and international institutional investors and was upsized by SEK 50 million on the back of

    ADDvise Group contemplates issuance of subsequent bonds of SEK 400 million

    ADDvise Group AB (publ) has mandated Pareto Securities AB and Skandinaviska Enskilda Banken AB (publ) to arrange a series of credit investor meetings commencing on 30 October 2023. A subsequent issue of senior secured bonds in an expected amount of SEK 400 million under the company's existing senior secured bond loan with a framework of SEK 2,000 million (the "Bond Issue") may follow, subject to inter alia market conditions. The proceeds from the contemplated Bond Issue shall be used to finance general corporate purposes (including capital expenditures and acquisitions).   For

    ADDvise Group’s nomination committee for the Annual General Meeting 2024

    In accordance with the resolution at the Annual General Meeting 2022 of ADDvise Group, the nomination committee for the Annual General Meeting 2024 shall comprise of representatives of the three largest shareholders by votes, according to the shareholders’ register as of 30 June 2023 maintained by Euroclear Sweden, and of the chairman of the board of directors. The representative appointed by the largest shareholder by votes shall be appointed chairman of the nomination committee. The nomination committee has now been appointed and consists of the following members: · Per-Anders

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe